1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 22, 2008, Pages 9780-9789

  Stefanachi, Angela ^a   Nicolotti, Orazio ^a   Leonetti, Francesco ^a   Cellamare, Saverio ^a   Campagna, Francesco ^a   Loza, Maria Isabel ^b   Brea, Jose Manuel ^b   Mazza, Fernando ^c   Gavuzzo, Enrico ^d   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d CNR   (Italy)

Author keywords

1,3 Dialkyl 8 (hetero)aryl 9 OH 9 deazaxanthines; Adenosine receptor antagonists; Structure affinity relationships; Structure selectivity relationships; X ray crystallography

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 HYDROXY 9 DEAZAXANTHINE DERIVATIVE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL TISSUE; AORTA; ARTICLE; COLON; CONTROLLED STUDY; DRUG DESIGN; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOLECULAR MODEL; NONHUMAN; PARTITION COEFFICIENT; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; RECEPTOR, ADENOSINE A2B; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

RATTUS;

EID: 54849413546     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.09.067     Document Type: Article

References (57)

1. Jacobson K.A., and Gao Z.-G. Nat. Rev. Drug. Discov. 5 (2006) 247
2. Moro S., Gao Z.-G., Jacobson K.A., and Spalluto G. Med. Res. Rev. 26 (2006) 131
3. Akkari R., Burbiel J.C., Hockemeyer J., and Müller C.E. Curr. Top. Med. Chem. 6 (2006) 1375
4. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. Pharmacol. Rev. 53 (2001) 527
5. Volpini R., Costanzi S., Vittori S., Cristalli G., and Klotz K.N. Curr. Top. Med. Chem. 3 (2003) 427
6. Baraldi P.G., Romagnoli R., Preti D., Fruttarolo F., Carrion M.D., and Tabrizi M.A. Curr. Med. Chem. 13 (2006) 3467
7. Strohmeier G.R., Reppert S.M., Lencer W.I., and Madara J.L. J. Biol. Chem. 270 (1995) 2387
8. Papassotiropoulos A., Hock C., and Nitsch R.M. Neurobiol. Aging 22 (2001) 863
9. Harada H., Osamu Asano O., Hoshino Y., Yoshikawa S., Matsukura M., Kabasawa Y., Nijima J., Kotake Y., Watanabe N., Kawata T., Inoue T., Horizoe T., Yasuda N., Minami H., Nagata K., Murakami M., Nagaoka J., Kobayashi S., Tanaka I., and Abe S. J. Med. Chem. 44 (2001) 170
10. Linden J. Mol. Pharmacol. (2005) 1385
11. Jacobson K.A., Hoffman C., Cattabeni F., and Abbracchio M.P. Apoptosis 4 (1999) 197
12. Xaus J., Valledor A.F., Cardo M., Marques L., Beleta J., Palacios J.M., and Celada A. J. Immunol. 163 (1999) 4140
13. Fozard J.R., and McCarthy C. Curr. Opin. Invest. Drugs 3 (2002) 69
14. Feoktistov I., and Biaggioni I. J. Clin. Invest. 96 (1995) 1979
15. Wolber C., and Fozard J.R. Naunyn Schmiedebergs Arch. Pharmacol. 371 (2005) 158
16. Holgate S.T. Br. J. Pharmacol. 145 (2005) 1009
17. Feoktistov I., Murray J.J., and Biaggioni I. Mol. Pharmacol. 45 (1994) 1160
18. Peyot M.-L., Gadeau A.-P., Dandré F., Belloc I., Dupuch F., and Desgranges C. Circ. Res. 86 (2000) 76
19. Feoktistov I., and Biaggioni I. Drug. Dev. Res. 39 (1996) 333
20. Jacobson K.A., Ukena D., Padgett W., Daly J.W., and Kirk K.L. J. Med. Chem. 30 (1987) 211
21. Müller C.E., Shi D., Manning M., and Daly J.W. J. Med. Chem. 36 (1993) 3341
22. Kim S.A., Marshall M.A., Melman N., Kim H.S., Müller C.E., Linden J., and Jacobson K.A. J. Med. Chem. 45 (2002) 2131
23. Grahner B., Winiwarter S., Lanzer W., and Müller C.E. J. Med. Chem. 37 (1994) 1526
24. Hayallah A., Sandoval-Ramirez J., Reith U., Schobert U., Preiss B., Schumacher B., Daly J.W., and Müller C.E. J. Med. Chem. 45 (2002) 1500
25. Vidal, B. J.; Esteve Trias, C.; Segarra Matamoros, V.; Ravina Rubira, E.; Fernandez Gonzales, F.; Loza Garcia, M. I.; Sanz Carreras, F.; WO Patent 03/000694, 2003.
26. Kalla, R.; Perry, T.; Elzein, E.; Varkhedkar, V.; Li, X.; Ibrahin, P.; Palle, V.; Xiao, D.; Zablocki, J. US Patent 6825349, 2004.
27. Palle, V.; Elzein, E.; Ibrahim, P.; Kalla, R.; Li X.; Perry T.; Varkhedkar, V.; Xiao, D.; Zablocki, J. WO Patent 05042534, 2005.
28. Wang, G.; Rieger, J. M.; Thompson, R. D. WO patent 05021548, 2005.
29. Kim Y.C., Ji X., Melman N., Linden J., and Jacobson K.A. Drug. Dev. Res. 47 (1999) 178
30. Kim Y.C., Ji X., Melman N., Linden J., and Jacobson K.A. J. Med. Chem. 43 (2000) 1165
31. Baraldi P.G., Tabrizi M.A., Preti D., Bovero A., Romagnoli R., Fruttarolo F., Abdel Zaid N., Moorman A.R., Varani K., Gessi S., Merighi S., and Borea P.A. J. Med. Chem. 47 (2004) 1434
32. Elzein E., Kalla R., Li X., Perry T., Gimbel A., Zeng D., Lustig K., Leung K., and Zablocki J. J. Med. Chem. 51 (2008) 2267
33. Vidal, B.; Esteve, C. WO Patent 03082873, 2003.
34. Esteve C., Nueda A., Di{dotless}az J.L., Beleta J., Cardenas A., Lozoya E., Cadavid M.I., Loza M.I., Ryder H., and Vidal B. Bioorg. Med. Chem. Lett. 51 (2006) 3642
35. Carotti A., Cadavid M.I., Centeno N.B., Esteve C., Loza M.I., Martinez A., Nieto R., Ravina E., Sanz F., Segarra V., Sotelo E., Stefanachi A., and Vidal B. J. Med. Chem. 49 (2006) 282
36. Stefanachi A., Brea J.M., Cadavid M.I., Centeno N.B., Esteve C., Loza M.I., Martinez A., Nieto R., Raviña E., Sanz F., Segarra V., Sotelo E., Vidal B., and Carotti A. Biorg. Med. Chem. 16 (2008) 2852
37. Carotti A., Stefanachi A., Ravina E., Sotelo E., Loza M.I., Cadavid M.I., Centeno N.B., and Nicolotti O. Eur. J. Med. Chem. 39 (2004) 879
38. Stefanachi A., Leonetti F., Cappa A., and Carotti A. Tetrahedron Lett. (2003) 1121
39. Senda S., Hirota K., Suzuki M., and Takahashi M. Chem. Pharm. Bull. 25 (1977) 568
40. Yoneda F., Motokura M., and Otagiri M. Chem. Lett. 9 (1981) 1273
41. Yoneda F., Motokura M., Kamishimoto M., Nagamatsu T., Otagiri M., Ukeama K., and Takamoto M. Chem. Pharm. Bull. 9 (1982) 3187
42. Smits, G.; Jin, X.; Gross, G.; Auchampach, J.; WO Patent 2003105666, 2003.
43. Fairley B., Botting N.P., and Cassidy A. Tetrahedron 59 (2003) 5407
44. Goodford P.J. J. Med. Chem. 28 (1985) 849
45. Kaliszan R., Nasal A., and Markuszewski M.J. Anal. Bioanal. Chem. 377 (2003) 803
46. Advanced Chemistry Development, Toronto, Canada.
47. BioByte Corp., Claremont, CA, USA.
48. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Deliv. Rev. 46 (2001) 3
49. Touchstone J. Advances in Thin-layer Chromatography (1982), John Wiley & Sons, New York
50. Burla M.C., Carmalli M., Carrozzini B., Cascarano G.L., Giacovazzo C., Palidori G., and Spagna R. J. Appl. Crystallogr. 36 (2003) 1103
51. SYBYL, version 7.1; Tripos Inc. (1699 South Hanley Road, St. Louis, MO 63144).
52. Stewart J.J.P. Quant. Chem. Prog. Exch. 10 (1990) 86
53. Pedretti A., Villa L., and Vistoli G. J. Mol. Graphics 21 (2002) 47
54. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
55. Prentice D.J., and Hourani S.M.O. Br. J. Pharmacol. 118 (1996) 1509
56. Furchgott R.F. In: Blaschko H., and Muscholl E. (Eds). Catecholamines (1972), Springer-Verlag, Heidelberg
57. Fozard J.R., Baur F., and Wolber C. Eur. J. Pharmacol. 475 (2003) 79